[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630961":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":42,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"AITD patients (observational cohort)",null,[12],"Diagnostic Test: Islet autoantibodies tested",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","Islet autoantibodies tested","This is an observational study. Eligible participants are patients aged 18-60 years with autoimmune thyroid disease (AITD), including Hashimoto's thyroiditis and Graves' disease, diagnosed by an endocrinology specialist. At baseline, demographic information, physical measurements, lifestyle factors, AITD-related clinical data, thyroid function, and thyroid autoantibody levels will be collected. Blood samples will also be obtained for measurement of islet autoantibodies (GADA, IA-2A, ZnT8A, and IAA) and their titers. Participants who test positive for islet autoantibodies will, within 2 months, undergo further evaluation including HbA1c testing, OGTT with insulin and C-peptide assessment, and HLA genotyping. A type 1 diabetes-related genetic risk score (GRS) will be constructed for all participants for exploratory analysis. No therapeutic intervention will be administered in this study.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Yong Gu","CONTACT","+86 02568303017","yong.gu@njmu.edu.cn",{"type":26,"investigatorFullName":21,"investigatorTitle":27,"investigatorAffiliation":28,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Deputy Director","The First Affiliated Hospital with Nanjing Medical University","100630961","risk-assessment-of-pancreatic-islet-autoimmunity-in-patients-with-aitd-100630961",false,"NCT07494474","Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD","Autoimmune Thyroid Disease Patients Identification and Assessment of Pancreatic Islet Autoimmune Risk","Inclusion criteria：\n\n1. Voluntary participation and signed informed consent\n2. Age 18-60 years\n3. Diagnosed with autoimmune thyroid disease, with positivity for at least one autoantibody: TPOAb, TgAb, TRAb, or TSI Exclusion criteria：\n\n1: Previously diagnosed diabetes mellitus or current diabetes treatment 2: Conditions severely affecting glucose metabolism (e.g., Cushing's syndrome, acromegaly) 3: Use of immunosuppressants or high-dose glucocorticoids within the past 3 months 4: Pregnancy or lactation 5: Severe cardiac, hepatic, or renal dysfunction, or any condition unsuitable for participation","ALL","18 Years","60 Years",{"count":40,"type":41},834,"ESTIMATED","2 Months","OBSERVATIONAL","This study aims to evaluate the risk of islet autoimmunity in patients with autoimmune thyroid disease (AITD), describe related clinical and laboratory characteristics, and explore the development of a risk assessment model based on clinical, laboratory, and genetic markers. Adults aged 18-60 years with confirmed AITD will undergo baseline assessment including demographic data, anthropometric measures, lifestyle factors, medical history, thyroid-related clinical information, thyroid function, and thyroid antibody testing. A baseline blood sample will be collected for measurement of islet autoantibodies (GADA, IA-2A, ZnT8A, and IAA). Participants with positive islet autoantibodies will undergo further evaluation of glucose metabolism and beta-cell function, including HbA1c, OGTT, insulin, and C-peptide testing. Genome-wide genetic data will be used to construct a type 1 diabetes-related genetic risk score, and additional HLA genotyping may be performed in autoantibody-positive participants. The study will assess the prevalence and profile of islet autoantibodies in AITD and identify clinical, laboratory, and genetic factors associated with islet autoantibody positivity.",[46],"Autoimmune Thyroid Disease",[48,49,50],"AITD","Islet autoantibodies","type 1 diabetes","NOT_YET_RECRUITING","2026-03-20",{"date":54,"type":55},"2026-03-27","ACTUAL",{"date":57,"type":41},"2026-08-31",{"date":59,"type":41},"2028-04-30",{"name":5,"class":6}]